NYSE American accepts AIM ImmunoTech's plan to regain listing compliance; deadline June 11, 2026

AIM ImmunoTech Inc.

Plan accepted under Sections 1003(a)(ii) and 1003(a)(iii) of NYSE American Company Guide.
AIM has until June 11, 2026 to meet minimum stockholders' equity requirements.
CEO Thomas K. Equels expressed confidence in executing the strategy.
Company continues oncology and antiviral pipeline development alongside compliance efforts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.